Mersana Therapeutics (STU:0M4) Accounts Payable & Accrued Expense : €16.05 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics Accounts Payable & Accrued Expense?

Mersana Therapeutics's quarterly accounts payable & accrued expense increased from Sep. 2024 (€18.62 Mil) to Dec. 2024 (€22.25 Mil) but then declined from Dec. 2024 (€22.25 Mil) to Mar. 2025 (€16.05 Mil).

Mersana Therapeutics's annual accounts payable & accrued expense declined from Dec. 2022 (€53.94 Mil) to Dec. 2023 (€26.79 Mil) and declined from Dec. 2023 (€26.79 Mil) to Dec. 2024 (€22.25 Mil).

Mersana Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Mersana Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Accounts Payable & Accrued Expense Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

20.13

36.32

53.94

26.79

22.25

Mersana Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															17.43	19.32	18.62	22.25	16.05

Mersana Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Mersana Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

MRSN:USA

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Mersana Therapeutics Headlines

No Headlines